Search

A former Nebraska state senator, John Kuehn, has appealed a second case to the Nebraska Supreme Court, seeking to invalidate the state’s voter-approved medical cannabis laws. Kuehn argues the laws are unconstitutional due to federal marijuana laws and that the creation of the Medical Cannabis Commission is an unlawful delegation of lawmaking authority. A district judge previously ruled Kuehn lacked "standing" to sue. The Nebraska Supreme Court will also hear a separate appeal from Kuehn regarding the validity of petition signatures for the ballot measures. Supporters of the medical cannabis laws view these challenges as an "abuse of power." < Back Former Nebraska Senator Seeks High Court Review In Medical Marijuana Case Seeking To Scrap Voter-Approved Legalization Law Jul 8, 2025 Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *“This latest appeal is just another desperate attempt to silence the will of Nebraskans, who overwhelmingly support safe, legal access to medical cannabis.”* *By Zach Wendling, Nebraska Examiner* A former state senator appealed a second case to the Nebraska Supreme Court seeking to invalidate the state’s voter-approved medical cannabis laws. Former state Sen. John Kuehn of Heartwell, a former member of the State Board of Health and a longtime marijuana opponent, filed the brief appeal request Saturday. Kuehn has asked the Nebraska Supreme Court to step in without going through the intermediate Nebraska Court of Appeals. The courts have not yet decided whether to take up the appeal. Kuehn seeks to argue that the 2024 voter-approved laws to legalize and regulate medical cannabis are unconstitutional because of federal laws against marijuana. “Plaintiff has a right to appeal directly to the Supreme Court because his case challenges the constitutionality of Nebraska laws,” the one-page filing states. Lancaster County District Judge Susan Strong on June 26 ruled that Kuehn could not prove “injury in fact,” known as “standing,” as a direct result of the medical cannabis laws. Strong disagreed with Kuehn’s arguments that he should be able to sue because taxpayer funds would help carry out the laws, such as employee time, and that the laws were a “matter of great public concern.” “Nebraska, like other states, has no shortage of citizen-taxpayers with strong political opinions. That is not necessarily a bad thing,” Strong wrote. “But it would be bad if all those citizens could sue whenever a law requires a government employee to do something.” Among Kuehn’s main contentions is that Nebraska shouldn’t be able to create a medical cannabis program because of federal law classifying marijuana as a Schedule I drug. A Schedule I drug is one that the federal government says has a high potential for abuse and no accepted medical uses. A bipartisan swath of advocates has called for rescheduling the drug for decades. Nearly 40 states, including Nebraska, have laws on the books for some form of medical cannabis program. Kuehn also argues that the creation of the new Nebraska Medical Cannabis Commission, the members of which are named in the lawsuit, is an unlawful delegation of lawmaking authority. The preemption case also names Gov. Jim Pillen (R), Secretary of State Bob Evnen, State Treasurer Tom Briese, Tax Commissioner Jim Kamm and the ballot sponsors who ushered the laws through the 2024 election. Nebraska Attorney General Mike Hilgers (R) and his office, who are representing the state defendants, had asked for the case to be dismissed. However, the AG’s Office did so after pledging to sue the Medical Cannabis Commission once it begins licensing medical cannabis establishments while making similar preemption arguments as Kuehn. Licensing must begin by October 1. The Nebraska Supreme Court, as early as September, will hear a separate appeal from Kuehn, Evnen and Hilgers that seeks to invalidate the medical cannabis laws. That case, targeting Evnen and the ballot sponsors, argues there were not enough valid petition signatures for the ballot measures to have been placed on the 2024 ballot in the first place. Strong presided over that earlier case and ruled last November in favor of the ballot measures. About 71 percent of Nebraskans voted to legalize the drug, and about 67 percent voted to regulate it. Crista Eggers, executive director of Nebraskans for Medical Marijuana, the 2024 campaign that ushered in the new laws, said the continued legal challenges “are nothing short of an abuse of power.” “This latest appeal is just another desperate attempt to silence the will of Nebraskans, who overwhelmingly support safe, legal access to medical cannabis,” Eggers said in a statement. “We will not be intimidated.” *This story was first published by Nebraska Examiner.* *Photo courtesy of M a n u e l.* The post Former Nebraska Senator Seeks High Court Review In Medical Marijuana Case Seeking To Scrap Voter-Approved Legalization Law appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

This post highlights New York's top concentrate, edible, and pre-roll brands for dispensary visits in July 2025, originally appearing on Leafly. < Back Discover New York’s best oil, edible, and pre-roll brands [July 2025] Jul 16, 2025 Leafly Staff Leafly Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link New York's best concentrate, edible, and pre-roll brands to check out on your next dispensary visit. The post Discover New York’s best oil, edible, and pre-roll brands [July 2025] appeared first on Leafly. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Amid a stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers are reiterating that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges. < Back Lawmakers Could Reschedule Marijuana With ‘Greater Speed And Flexibility’ Than Administration Officials, Congressional Researchers Say Jun 18, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Amid a stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers are reiterating that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges. In an “In Focus” brief published by the Congressional Research Service (CRS) last week, analysts provided an overview of the different mechanisms through which scheduling actions can be implemented, noting the limitations of the process that the Biden administration initiated—and that the Trump administration has since inherited—to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). “There are two ways in which substances can be scheduled under the CSA: Congress can schedule substances by enacting legislation, or the Attorney General (in conjunction with the U.S. Department of Health and Human Services, or HHS) can schedule substances via an administrative process laid out in the CSA,” CRS said. For this report, which is an update to an earlier analysis CRS put out last year, researchers detailed various instances where Congress has stepped in and made a scheduling decision—such as the federal legalization of hemp under the 2018 Farm Bill. “Congress placed numerous substances in Schedules I through V when it enacted the CSA in 1970,” it says. “Since the CSA’s enactment, most subsequent scheduling changes have been made by DEA via the rulemaking process, but Congress has at times enacted legislation to schedule controlled substances or change the status of existing controlled substances.” “There are several reasons why Congress might decide to schedule or reschedule substances via legislation,” it says. “For instance, compared to administrative scheduling, legislative scheduling may offer greater speed and flexibility.” “Administrative scheduling under the CSA proceeds via formal rulemaking, which generally takes months or years to complete. In making scheduling decisions, DEA is required by statute to make certain findings with respect to each substance’s potential for abuse and accepted medical use,” it continues. “DEA scheduling orders (other than temporary scheduling orders) are subject to judicial review, including consideration of whether the agency properly applied the relevant statutory standards.” To that point, it did take 11 months for HHS under the Biden administration to complete its review into cannabis and make an initial rescheduling recommendation. DEA then completed a separate review before the Justice Department formally proposed moving marijuana to Schedule III—but even then, there have been months of delay in the administrative hearing process to potentially finalize the rule. Congress, on the other hand, could reschedule or deschedule marijuana more quickly and with a lower threat of a judicial challenge, CRS said. “Congress is not bound by the CSA’s substantive or procedural requirements,” the report says. “This means that it can schedule a substance immediately, regardless of whether the substance meets the statutory criteria. While scheduling legislation may also be challenged in court, the scope of judicial review of legislation is typically more limited than judicial review of regulations.” It also says legislative action “may be the only way to permanently schedule large classes of substances” such as fentanyl-related substances, given the intensive statutory requirements imposed on DEA under the CSA. “Relatedly, the CSA provides DEA with limited options for regulating controlled substances,” CRS said. “The CSA established Schedules I-V, with each schedule carrying a defined set of regulatory controls and penalties for unauthorized activities. If DEA decides to control a substance under the CSA, it must place the substance in one of the existing schedules.” “The agency has asserted some authority to tailor controls to specific substances, but it cannot create new schedules or implement regulations or exceptions from control that are not authorized under the CSA. If Congress wishes to regulate a controlled substance in a way that does not fit within the existing CSA framework, or allow DEA to do so, it must enact legislation.” Additionally, the report notes that while DEA is bound to consider certain international treaty obligations when it comes to drug scheduling, those same commitments “do not prevent Congress from exercising its constitutional authority to enact new laws, even when doing so might cause the United States to violate its treaty obligations.” Meanwhile, last month a Senate committee advanced the confirmation of Terrance Cole to become the administrator of DEA amid the ongoing review of a marijuana rescheduling proposal that he’s refused to commit to enacting. Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—said he would “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.” However, during an in-person hearing before the Judiciary Committee in April, he said examining the rescheduling proposal will be “one of my first priorities” if he was confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see. “I’m not familiar exactly where we are, but I know the process has been delayed numerous times—and it’s time to move forward,” he said at the time. “I need to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process.” Cole also said he feels it’s appropriate to form a “working group” to look at the federal-state marijuana law disconnect in order to “stay ahead of it.” DEA recently notified an agency judge that the proceedings are still on hold—with no future actions currently scheduled. The matter sat without action before an acting administrator, Derek Maltz, who has called cannabis a “gateway drug” and linked its use to psychosis. Maltz has since left the position. Most Marijuana Consumers Oppose Trump’s Cannabis Actions So Far, But Rescheduling Or Legalization Could Bolster Support, Poll Shows *Photo courtesy of Chris Wallis // Side Pocket Images.* The post Lawmakers Could Reschedule Marijuana With ‘Greater Speed And Flexibility’ Than Administration Officials, Congressional Researchers Say appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Connecticut legalized recreational cannabis use four years ago, leading to significant changes in the medical marijuana market. Recreational sales have surpassed medical purchases since May 2023. Medical users receive tax exemptions and can purchase products unavailable to recreational users, and are not subject to potency restrictions. The state collected $49.4 million in cannabis revenue in FY 2024. Most dispensaries are now hybrid (medical and recreational) or recreational only, with only one exclusively medical dispensary remaining. Medical card holders are prohibited from purchasing firearms due to federal law. < Back What’s Changed Since Connecticut Legalized Adult-Use Marijuana 4 Years Ago? Jun 30, 2025 Marijuana Moment Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link *Not only have recreational sales increased, but medical purchases have made up less than half of the state’s cannabis market retail sales since May 2023.* *By Sasha Allen, CT Mirror* July 1 marks four years of legalized recreational cannabis use in Connecticut, and with legalization came major changes to the medical marijuana market. A law enacted in 2012 allowed the purchase and use of cannabis for medical reasons only. But in 2021, the state legalized recreational use for everyone 21 and older. Statewide recreational retail sales began in January 2023, and by May 2023, recreational sales accounted for the majority of state cannabis retail sales, a trend that has continued to today. Connecticut was the 19th state to legalize recreational marijuana. Under state law, anyone 21 or older without a medical card is allowed to possess up to 1.5 ounces of cannabis flower or other cannabis product equivalent in public and up to 5 ounces in their private residence. Medical cardholders can posses up to 5 ounces of cannabis on their person. Not only have recreational sales increased, but medical purchases have made up less than half of the state’s cannabis market retail sales since May 2023. Connecticut was the 19th state to legalize recreational marijuana. Both medical and recreational dispensaries sell similar products, but medical users who are using the product to treat “debilitating medical conditions” aren’t subject to the cannabis tax. Medical users can also buy other products that recreational users cannot, including capsules, tablets, pills, sublinguals and suppositories. Medical users are also not subject to potency restrictions, while recreational cannabis is currently capped at 30 percent THC for cannabis flower and 60 percent THC for concentrate products other than vapes. However, as of October 1, 2025, the cap for raw flower will be raised to 35 percent THC and 70 percent THC for concentrates other than vapes. The cannabis tax is dependent on both the product and the amount of THC; edible products are taxed the most heavily per milligram of THC and plant products the least. For an eighth of flower that’s 15 percent THC, for the tax currently sits at around 9.4 percent, fluctuating based on product pricing. Edibles are subject to a tax of $0.0275 per milligram of the product’s total THC content. Medical card holders are required to apply for renewal annually, which involves a consultation fee with health care providers that can range from $100 to $350 for users 18 and older. For users under 18, users must have a condition specified by the legislature for medical usage as well as parental consent and a caregiver arrangement. Because cannabis usage is federally illegal, medical card holders are prohibited from purchasing firearms, and everyone applying for a firearm is required to disclose their usage of cannabis and other federally controlled substances. Federal law bars all cannabis users from owning a firearm. Each hybrid or recreational cannabis retailer registered in Connecticut must pay the cannabis tax, which varies by product. The state cannabis tax brought in $21.3 million in state revenue for FY 2024. Overall, the sales tax—along with state sales tax, municipality sales tax and licensing and conversion fees for dispensaries—brought in $49.4 million in cannabis revenue for FY 2024. While there are dozens of products on the market, usable cannabis flower, which is just the dried plant, brings in the most sales across the medical and recreational markets. Overall, in May 2025, recreational cannabis retail sales were $18.7 million. Medical retail sales were $6.6 million. There is only one exclusively medical dispensary in the state. The rest of the dispensaries have transitioned and cater to both the recreational market and the medical market as hybrid dealers, or just the recreational market. Statewide, there are 36 recreational dispensaries and 35 hybrid dealers. However, the number of dispensaries fluctuates. Back in January 2023, only nine hybrid dispensaries existed. Numbers from around February 2025 showed 64 dispensaries in the state—eight fewer than are currently open. *This article first appeared on CT Mirror and is republished here under a Creative Commons Attribution-NoDerivatives 4.0 International License.* Embracing Marijuana Legalization Could Help GOP Win Over More Young Voters, Trump’s First Attorney General Pick Suggests *Photo courtesy of Philip Steffan.* The post What’s Changed Since Connecticut Legalized Adult-Use Marijuana 4 Years Ago? appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

The new machine's wash cycle capacity is up to 9,000 grams of fresh frozen or 2,100 grams of dry material. < Back Lowtemp Industries Launches Mini Osprey 2.0, a Next-Gen, 30-Gallon Hash Washing Machine Jan 8, 2026 Staff Cannabis Business Times Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The new machine can process up to 9,000 grams of fresh frozen or 2,100 grams of dry material per wash cycle. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Scammers are impersonating Fresh Delaware, a state-licensed cannabis business, by offering illegal delivery services in the Newark area, including the University of Delaware campus, which is prohibited under state law. The Division of Alcohol & Tobacco Enforcement (DATE) is investigating reports of fraudulent business cards and flyers that falsely claim delivery, and they urge the public to provide any information about the scheme. Fresh Delaware confirmed they do not offer deliveries. < Back Delaware Scam Claiming to Represent State-Licensed Dispensary Offering Illegal Cannabis Deliveries Oct 21, 2025 TG Branfalt Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Scammers in Delaware claiming to represent Fresh Delaware – a state-licensed cannabis business – are saying they will deliver products to customers, which is not allowed under state law. The state Division of Alcohol & Tobacco Enforcement (DATE) said it has received reports of fraudulent business cards and flyers in the Newark area, which includes the University of Delaware campus. “The public needs to know that no licensed recreational marijuana dispensary in Delaware is permitted to deliver marijuana or marijuana products. Any business claiming to offer such delivery services is operating illegally.” — DATE in a press release The flyers include the Fresh Cannabis name and logo, while one claims “quick delivery for on campus students” and offers a free eighth for signing up for the service and a free ounce for student referrals. A Fresh Delaware employee told Delaware Online that the dispensary does not offer deliveries. DATE said it is actively investigating the scheme and urged the public to provide the agency with any information about the materials. Jon Peterson, a spokesman for DATE, told the Newark Post that “The impostors are attempting to mislead potential customers into purchasing marijuana products illegally.” < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

A new Virginia government cannabis commission will meet next week to discuss future marijuana laws, likely leading to a revised proposal for retail sales. While marijuana use and possession have been legal since 2022, retail sales are still forbidden, fueling an illicit market. Governor Glenn Youngkin has twice vetoed proposals for regulated sales, but with his term ending, the next governor will likely decide the fate of retail cannabis. The commission, in place until mid-2028, will gather public input and make recommendations on various policy matters for Virginia's transition to a commercial adult-use market, including licensing, taxes, employment protections, and labor union agreements. Advocacy groups like Marijuana Justice and NORML plan to participate, while the Virginia Cannabis Association does not, focusing instead on reintroducing previously vetoed legislation. The outcome of the upcoming gubernatorial election is seen as crucial for the future of cannabis retail in Virginia. < Back New Virginia Cannabis Commission Meeting Next Week Will Help Shape Recreational Marijuana Sales Rules Under The Next Governor Jul 1, 2025 Ben Adlin Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A newly reformed government cannabis commission in Virginia will meet next week to discuss the future of marijuana law in the commonwealth—a process widely expected to result in a revised proposal to legalize retail sales of the drug. Convened as part of a House joint resolution passed by lawmakers earlier this year, the group is set to spend the coming months gathering public input and making recommendations on an array of policy matters around Virginia’s would-be transition into a full-fledged adult-use commercial cannabis market. Those include fundamentals like licensing and tax details along with related issues such as paraphernalia, employment protections and labor union agreements. Use and possession of marijuana has been legal in Virginia since 2022, but retail sales remain forbidden—a situation that’s helped fuel a multibillion-dollar illicit market. Despite efforts by Democrats in past years to legalize and regulate the retail system, Gov. Glenn Youngkin (R) has stood in the way of the reform, twice vetoing proposals passed by lawmakers. “There’s kind of a good-news, bad-news with retail cannabis legalization in Virginia,” Del. Paul Krizek (D), who sponsored the resolution creating the new body—formally called the Joint Commission to Oversee the Transition of the Commonwealth into a Retail Cannabis Market—told Marijuana Moment in a recent interview. The bad news, he said, is that lawmaker infighting over whether and how to regulate marijuana has meant “we’re unable to provide Virginians with a tested, well regulated retail market” even years after possession became legal. “The good news is it’s given us a little bit of time to work on perfecting this legislation that we’re going to bring back next session,” he continued. “It’s also given us the time to…get more input from the public and from the stakeholders, and to really move cannabis from the street corner to behind an age-verified retail counter.” In the short-term, Krizek and others say the commission’s conversation will inform an updated bill to introduce in the coming year. With Youngkin term-limited and unable to run for re-election in November, his replacement is likely to decide whether regulated products will become available in the commonwealth in the next few years. Whatever happens, the body is scheduled to remain in place until mid-2028, which the lawmaker said will allow members to keep at the work—whether that means continuing to explore the possibility of retail sales or monitoring a fledgling commercial system as gets off the ground. The commission created by Krizek’s bill, HJ 497, consists of six lawmakers from the House and four from the Senate. A similar commission previously existed in the commonwealth, but the law creating that body sunsetted last year and the group disbanded. Most business at the commission’s first meeting, on July 9, will be housekeeping: things like setting agendas and ground rules for meetings, electing officers—Krizek said he hopes to be selected as chair, with Sen. Adam Ebbin (D) as vice chair—and laying out expectations for process ahead. From there, he emphasized, the bulk of the commission’s work will involve hearing from stakeholders and the public. “This is all about a public process with public input, not just stakeholders, but the public in general,” Krizek told Marijuana Moment. “One of the goals, I’m certain, will be to get as much public information [as possible], especially from our stakeholders.” He said he intends to use the recent legal sales bill that was vetoed by Youngkin as a starting point “with a few small tweaks” but also pointed to other issues he hoped the commission would take up, such as expanding cannabis-related employment protections to include non-medical marijuana use by adults, evaluating proposed tax rates on paraphernalia and adding provisions around labor union organizing. Asked whether the matters would be part of a comprehensive sales bill or dealt with on a more piecemeal basis, the lawmaker emphasized that the committee’s focus for now is on understanding policy issues rather than strategizing how to pass legislation. “You have to tackle it policy first, and you worry about the tactics as you go,” he said. Among the organizations expected to participate in the commission process are Marijuana Justice and NORML, which both appeared before the previous iteration of the body. Chelsea Higgs Wise, executive director of Marijuana Justice, said she’s “excited about the opportunity for public comment and expert testimony,” calling the commission “an opportunity for a melding of the minds.” “These legislators, many of them are new to the cannabis industry, and so this is an opportunity for them to learn best practices, hear from trusted advocates and organizers and invite in the experts…to make smart decisions,” she said. “The majority of them have a history of standing on justice, equity and being open to learning how cannabis can really benefit Virginia,” she added of the commission’s members. “I am very excited for this commission to hear and craft the future of Virginia cannabis.” Among the priorities Marijuana Justice has for the conversation is a review of micro business eligibility provisions, which Higgs Wise said could be too wide in scope, as well as how adult-use cannabis operators could effectively compete with large, existing medical marijuana companies. “Centering corporations, centering big cannabis, is not necessarily what’s best for a Virginia-based industry,” she said. “We really want to have in-depth conversations about the start date of sales and what that will mean for people that are just getting started, versus those that are already operational either with hemp or with medical cannabis.” JM Pedini, development director for the advocacy group NORML and executive director for Virginia NORML, told Marijuana Moment that the commission “has consistently provided an excellent opportunity for both lawmakers and members of the public to participate in cannabis policy discussions before the legislative session begins” and encouraged interested members of the public to attend the panel’s meetings. But Pedini also stressed the importance of getting out the vote later this year, especially in the governor’s race. “Ultimately, it is the outcome of this November’s election that will determine the fate of cannabis retail in Virginia,” they said. “There are only two choices. Voters can either elect a governor who will sign a retail sales measure, or one who will double down on prohibitionists’ attempts to roll back cannabis freedoms in the commonwealth.” One advocacy group not planning to engage with the new commission is the Virginia Cannabis Association (VCA). “To be quite frank, we’re not going to participate in any of these meetings,” said Jason Blanchette, the organization’s president. “I don’t really know what’s going to come out of it.” “I’m not really looking to get involved in that at all,” he continued of the commission’s work, explaining that VCA is focused on reintroducing the same bill that lawmakers sent to Youngkin in the past two years. “We are going to push like heck the bill that we have already spent an enormous amount of time getting it to the finish line,” Blanchette said. “The hope is to pass this thing in January so they don’t have to keep monkeying around here.” He also doubted the makeup of the panel, saying that “six delegates and four senators is not the way to do it.” He’d rather see members of the cannabis industry represented on the body itself. “I think it’s going to be mandatory for them to have a medical operator representative. It’s going to be mandatory to have a grower-farmer representative. It’s going to be mandatory to have a retail representative,” he said. “Public input…versus having a seat at the table are two totally different things.” Blanchette said he’s nevertheless bullish on the chances for reform, predicting that after November’s election, Democrats will control not only the governor’s office but also both the Senate and the House of Delegates. “They more than likely are going to have a trifecta,” Blanchette said of the party. “And that’s what makes 2026 the year this has to pass.” *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Advocates like Pedini have pointed out that if the next governor isn’t open to legalizing retail sales, that could set back the effort until 2030 or later. It could also affect more incremental reforms. For example, in May Youngkin vetoed a bill that would have allowed deliveries of medical marijuana directly to patients at locations other than their own homes. It would have also updated product labeling requirements so packaging would more clearly indicate THC and CBD levels. In March, after the legislature passed the legislation, Youngkin recommended an amendment that would remove language to allow marijuana to be delivered to places other than a patient’s private residence. Lawmakers later declined to make that change, however, and sent the unamended bill back to the governor. The proposal had strong support in both chambers, passing the Senate on a 30–10 vote and winning final approval in the House on an 84–14 margin. But Youngkin nevertheless rejected it. “While accurate labeling is essential to ensure patients receive consistent and safe medical cannabis,” he wrote in a veto message, “this bill would codify the ability to deliver medical cannabis to commercial businesses and temporary residences, raising public safety and regulatory concerns. Permitting deliveries to businesses—including locations where substance abuse, gambling, or other high-risk activities may occur—creates unnecessary risks for diversion, theft, and unintended access by minors.” Pedini at NORML described the veto at the time as “yet another example of the attacks on legal cannabis and responsible consumers that are underway across the nation.” Youngkin in March also vetoed a host of other drug reform proposals passed by lawmakers, including the legal sales bill and another to authorize the prescription of a synthetic form of psilocybin as soon as the federal government authorizes its use. Beyond the legal sales and psilocybin bills, the governor also rejected a number of other cannabis-related reforms this session, including efforts to resentence people serving time for cannabis offenses and protect the parental rights of those who legally use the drug. Youngkin agued in a veto statement that legalizing sales of adult-use marijuana “endangers Virginians’ health and safety.” “States following this path have seen adverse effects on children’s and adolescents’ health and safety, increased gang activity and violent crime, significant deterioration in mental health, decreased road safety, and significant costs associated with retail marijuana that far exceed tax revenue,” the governor claimed. “It also does not eliminate the illegal black-market sale of cannabis, nor guarantee product safety.” Even before the start of the current legislative session, Youngkin’s office had signaled it had no interest in the reform. Asked by Virginia Public Media (VPM) late last year about the likelihood of a veto, Christian Martinez, a spokesperson for the Youngkin, told the outlet: “I think you can cite the fact that time and time again he has been very clear on that.” Reform advocates are already watching to see where his possible replacements stand on legalization and other cannabis policy changes. Two frontrunners for the position—Republican Lt. Gov. Winsome Earle-Sears and Democratic former U.S. Rep. Abigail Spanberger—have starkly different views on the reform. Earle-Sears recently echoed Youngkin’s views, saying of legalization: “There’s no hope in that.” She’s also said marijuana is a gateway drug and that she fired a previous employee for using it. Spanberger, meanwhile, voiced support for a regulated retail market. “We need a formalized, legal, emerging cannabis market,” she said. “We also need to make sure that [tax] revenues flow into Virginia and are used to strengthen our communities and public schools.” Ebbin, the senator who is expected to become vice chair of the new commission, suggested that the outcome of the election will determine the future of cannabis policy in Virginia. “I think we will finally see regulated sales after the 2026 legislative session,” he told Marijuana Moment, “assuming a pro-regulated market candidate, like Abigail Spanberger, is elected governor.” Marijuana Industry Lawsuit Has ‘Zero Chance’ Of Being Heard By Supreme Court, Former DOJ Lawyer Says (Op-Ed) *Photo courtesy of Mike Latimer.* The post New Virginia Cannabis Commission Meeting Next Week Will Help Shape Recreational Marijuana Sales Rules Under The Next Governor appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Marijuana Saw Some Big Moments In 2025—From Trump’s Rescheduling Order To State Legalization Momentum < Back Marijuana Saw Some Big Moments In 2025... Dec 30, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link As 2025 comes to a close, the cannabis world is reflecting on the sometimes dizzying series of political, legal and cultural shifts that took place this year—and looking ahead to further developments that advocates and industry stakeholders will be navigating in the new year. Top of mind, of course, is President Donald Trump’s executive order this month directing the attorney general to complete the process of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA), marking perhaps the most significant administrative cannabis action in U.S. history. But from the White House to the U.S. Supreme Court to state legislatures across the country, there were additional meaningful marijuana developments this year. That includes the upending of key provisions of federal law that had legalized hemp and its derivatives. What 2026 will bring is yet to be seen. Many eyes will be focused on how the Justice Department approaches the president’s rescheduling directive, but some see opportunities for further reform—with optimism that there’s momentum to see through a bipartisan banking bill, for example. And hopes are high that additional states could legalize cannabis in 2026—though advocates are also preparing to fight prohibitionist efforts to roll back wins that have already been achieved in other states. *Looking back at 2025, here are the top marijuana moments:* *Trump signs marijuana rescheduling executive order* After campaigning on a promise to reschedule marijuana ahead of his second term–and months of relative silence on cannabis issues after taking office—Trump in December signed an executive order directing the attorney general to expeditiously complete the process of moving cannabis to Schedule III. The reform hasn’t been finalized yet, but if it is, the policy change would mark one of the most substantial changes to federal marijuana laws since its prohibition over half a century ago. Rescheduling wouldn’t legalize the plant, but it would recognize its medical value, allow marijuana businesses to take federal tax deductions and loosen certain research barriers. *In addition to rescheduling, Trump administration announces policy to expand access to CBD* Trump’s executive order also urged Congress to examine updating the definition of hemp to ensure that full-spectrum CBD is accessible to patients. If lawmakers do so, it could mitigate some concerns in the sector about a recent spending bill the president signed with provisions that would broadly ban consumable hemp products. A further redefinition of hemp would be part of a novel proposal to allow Medicare recipients to access non-intoxicating CBD that’d be covered under the federal health care plan. *U.S. Supreme Court declines to take landmark case challenging prohibition* Advocates and stakeholders were handed a defeat from the Supreme Court in December after justices declined to accept a case challenging the constitutionality of federal marijuana prohibition—an issue that even one of the bench’s more conservative members, Justice Clarance Thomas, had previously argued must be resolved amid the state legalization movement. Massachusetts-based marijuana businesses had asked the court to take their case because they argued that federal law unconstitutionally prohibits intrastate cannabis activity, contravening the Commerce Clause. *Justices weigh federal gun ban for marijuana consumers* In October, meanwhile, the Supreme Court agreed to hear a case on the constitutionality of a federal law prohibiting people who use marijuana or other drugs from buying or possessing firearms. The Trump administration has argued that the policy “targets a category of persons who pose a clear danger of misusing firearm” and should be upheld. *Trump signs spending bill with hemp ban provisions* In November, the president signed appropriations legislation that includes provisions to ban most consumable hemp products that have proliferated since the crop was legalized under the 2018 Farm Bill that Trump signed during his first term in office. The hemp components won’t be implemented until one year after enactment, however, and stakeholders and certain lawmakers say that window could provide an opportunity to advance legislation to create an alternative regulatory model for cannabinoid products. *Congressional lawmakers file cannabis bills and hold hearings on various marijuana issues* A slew of cannabis bills were filed or refiled for the 119th Congress in 2025, including those that would federally legalize marijuana, take steps to prepare for the eventual end of prohibition, stop the implementation of a federal hemp THC product ban, prevent people from using federal financial assistance at marijuana dispensaries, protect military veterans from losing government benefits for using medical cannabis in compliance with state law and more. None of those measures advanced to enactment, though lawmakers did approve amendments to a spending bill that would have authorized U.S. Department of Veterans Affairs (VA) doctors to issue medical marijuana recommendations to military veterans and support psychedelics research and access. Even though versions of the veterans’ medical cannabis amendment were approved by both the House of Representatives and Senate, the reform was stripped out of a final spending bill sent to the president. And while there’s been disappointment about the lack of progress on cannabis industry banking issues, a Senate subcommittee did take up the subject at a hearing in December that featured a former state marijuana regulator as a witness. *Trump administration rescinds Biden-era marijuana enforcement guidance* The Trump administration quietly rescinded guidance implemented under former President Joe Biden that ordered U.S. prosecutors to be “extremely cautious” about how to handle cannabis cases. In November, the U.S. Attorney’s Office for the District of Wyoming disclosed that the guidance was rescinded in September, and it said cases involving marijuana would consequently be “rigorously” enforced on federal land. *Federal immigration officials raid California marijuana business* Marijuana farms operated by a major state-licensed business in California were raided by federal officials in July. The action didn’t appear to be a targeted effort by the federal government against the state-legal cannabis industry specifically, as other reports indicated that Immigration and Customs Enforcement (ICE) agents had been involved in numerous enforcement actions in the area at the time. *American medical cannabis patient released from Russian prison after possession conviction* An American who was released from a Russian prison over marijuana possession he obtained as a lawful medical cannabis patient in Pennsylvania was among President Donald Trump’s invited guests at a speech before a joint session Congress on in March. Marc Fogel—who was serving a 14-year sentence in Russian after being convicted of “drug smuggling” over possession of a half-ounce of cannabis and whose release was secured as part of a prisoner swap—was in attendance at the president’s speech on Capitol Hill. *Vice President JD Vance and U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. participate in conference with psychedelics panel* Vance, Kennedy, Food and Drug Administration (FDA) Commissioner Marty Makary and other top Trump administration officials attended a “Make America Healthy Again” summit that featured a session on the therapeutic potential of psychedelics. Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services (CMS), and Katie Miller, wife of Trump adviser Stephen Miller, were also among those who attended the event, which was meant to broadly showcase the MAHA agenda and areas of innovation in public health. *State-level legalization efforts gain momentum* Although no additional states enacted cannabis legalization laws in 2025, reform legislation did advance—demonstrating momentum that advocates hope to build upon in 2026. The Pennsylvania House of Representatives in March passed a bill to legalize marijuana sales through a novel system of state-owned dispensaries, but it was rejected in the GOP-controlled Senate. Two Hawaii Senate panels in February approved a broad bill that would legalize adult-use marijuana and bring together hemp and cannabis regulation under a single state agency. Also, the full Senate gave approval to a bill that would, among other changes, allow healthcare providers to recommend cannabis to treat any condition they believe it would benefit. The New Hampshire House of Representatives approved bills to legalize marijuana, decriminalize the use and possession of psilocybin by adults and double the amount of medical cannabis that state-registered patients can purchase and possess. The Virginia legislature approved legislation to legalize adult-use cannabis sales, only to have it once again vetoed by the governor. *Marijuana sales launch in Delaware, Minnesota and Kentucky* Adult-use marijuana sales began in Delaware and Minnesota in 2025, while medical cannabis dispensaries opened their doors in Kentucky. *States impose hemp bans amid concerns over intoxicating cannabinoid products* As congressional lawmakers moved to recriminalize certain hemp products, red and blue states—from Texas to Ohio to California—took steps on their own to restrict the sale of consumable cannabinoids. *Virginia elects pro-cannabis governor as legislative commission unveils legalization plan* Efforts to legalize adult-use marijuana sales in Virginia got a boost with the election of Abigail Spanberger as the state’s next governor. And the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market subsequently unveiled a much-anticipated proposal to legalize recreational marijuana sales that it is recommending lawmakers pass during the 2026 session. *Florida campaign makes another run to legalize adult-use marijuana through the ballot* The campaign Smart & Safe Florida filed a new cannabis legalization initiative that they hope will go before voters next November. And after collecting what they estimated to be more than one million signatures to secure ballot placement amid litigation, Florida’s attorney general asked the state Supreme Court to review the constitutionality of the proposal. *Anti-marijuana activists plot to undermine state legalization laws* In three states—Arizona, Maine and Massachusetts—prohibitionist activists have made moves to put initiatives on the ballot next year to roll back key components of adult-use legalization laws, focusing largely on the elimination of the commercial market. *More developments arise in state-level drug policy ballot campaigns * An Idaho campaign unveiled a since-certified initiative to put medical marijuana legalization on the state’s 2026 ballot. In Oregon, activists withdrew a ballot proposal to legalize marijuana social consumption lounges. And in Alaska, a campaign said it failed to collect enough signatures to put an initiative to legalize certain psychedelics such as psilocybin and DMT on the ballot next year—but activists emphasized that the “work is far from over” as they shift focus to placing the reform measure before voters in 2028. *New York marks milestones in marijuana market expansion* After a rocky rollout of the state’s adult-use marijuana law, marred by lawsuits and regulatory complications, New York officials in November celebrated the opening of its 500th legal cannabis dispensary—touting the fact that there have been $2.3 billion in sales since the market launched, supporting an estimated 25,000 jobs across the industry. *States move forward with psychedelics reform* Over the summer, Texas Gov. Greg Abbott (R) signed into law a bill to create a state-backed research consortium to conduct clinical trials on ibogaine as a possible treatment for substance use disorders and other mental health conditions. And in Arizona, officials approved and funded a first-in-the-nation clinical trial investigating the potential of whole mushroom psilocybin to treat post-traumatic stress disorder (PTSD) in first responders and military veterans. *New Jersey gubernatorial election raises hopes for reform* New Jersey voters elected U.S. Rep. Mikie Sherrill (D-NJ) to serve as the state’s next governor, meaning there’s now a decidedly clearer path to advancing a marijuana policy reform long awaited by consumers and advocates in the Garden State: A home grow option. *Target launches pilot program for hemp beverage sales* In one of the latest examples of the normalization of cannabis in mainstream commercial marketing, the retail giant Target soft launched sales of THC-infused beverages at select stores in Minnesota. *Edible Arrangements offshoot embraces the hemp industry* The company behind Edible Arrangements is entering the cannabis market, launching a new delivery service for hemp products. Edible Brands, best known for its line of ornate fruit arrangements, announced in March that it was expanding to start selling different kinds of edibles: hemp gummies, drinks and supplements. *Photo courtesy of Philip Steffan.* The post Marijuana Saw Some Big Moments In 2025—From Trump’s Rescheduling Order To State Legalization Momentum appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Kentucky's first medical marijuana cultivation facility has harvested its initial crop, and patients may have access to it as early as November. Governor Andy Beshear announced the approval of another large cultivation facility, Natural State GreenGrass CannaCo, and expects the medical cannabis market to expand significantly. The governor also noted delays in implementation and signed executive orders to waive renewal fees for patient cards and protect patients who obtain medical marijuana outside Kentucky. He also sent letters to federal officials urging the rescheduling of marijuana and the protection of gun rights for medical cannabis patients. Over 100 cities and counties in Kentucky have approved local ordinances for medical cannabis businesses. < Back Kentucky Cultivator Harvests State’s First Medical Marijuana Crop As Governor Predicts Farmers Will ‘Grow A Whole Lot More’ Oct 3, 2025 Kyle Jaeger Marijuana Moment Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A Kentucky medical marijuana cultivation facility has harvested its first yield of cannabis, and patients could gain access to it by next month, a top regulator says. Meanwhile, the governor says licensed businesses are about to “grow a whole lot more” as the program gets underway. Cannon Armstrong, executive director of the Office of Medical Cannabis (OMC), said one of the state’s cultivators “produced their first harvest, and it’s up to the cultivator and the licensee on where they move and when they move on that.” “I suspect that if we’re going to try and say timeframes—that it’ll definitely be before the end of the year, we’re hopeful that it may be November,” he told WAVE 3. That pushes back the timeline slightly after Armstrong previously estimated a few weeks ago that sales could begin this month—but Gov. Andy Beshear (D) said this is just the start of a robust medical cannabis market in the commonwealth. “Since taking office, my administration has been committed to providing access to health care and safe communities for all Kentuckians,” the governor said. “One of our priorities is ensuring that Kentuckians that are suffering from serious medical issues like cancer, PTSD or multiple sclerosis can have safe access to medical cannabis as soon as possible to get the relief they need.” He also announced that, although licensed operators are actively growing cannabis plants to bring to market, “we’re about to grow a whole lot more,” adding that as of Thursday, OMC approved “another cultivator to begin cultivation activities here in Kentucky, and this one is a big one.” Beshear was talking about Natural State GreenGrass CannaCo, a tier III cultivation facility, which is “one of the two largest cultivation facilities in Kentucky.” “They’ll eventually expand all 25,000 square feet of cultivation space,” he said. “This operator and so many more will help us ensure for years to come that Kentuckians suffering from serious medical conditions can get the relief they deserve.” Last month, Beshear said he thought medical marijuana would be available to Kentucky patients by the end of 2025. “The medical marijuana program is moving forward,” he said at a press briefing at the time. “I think most of our dispensaries now have their home address [and] are set about where they’re going to be, but [for] some of the inspections that have to happen in dispensaries, they have to have product that’s there,” he said. “So I do believe they’ll be operating before the end of the year.” Those comments came roughly a month after the governor announced that the state’s first medical cannabis dispensary has officially been approved for operations, calling it “another step forward as we work to ensure Kentuckians with serious medical conditions have access to the medicine they need and deserve. He previously touted an earlier “milestone” in the state’s forthcoming medical marijuana program, with a licensed cultivator producing “the first medical cannabis inventory in Kentucky history.” Beshear’s office has said that other cannabis licensees, including processors and testing labs, are expected to become operational soon. In July, Beshear sent a letter to President Donald Trump, urging him to reject congressional spending bill provisions that would prevent the Justice Department from rescheduling marijuana. In the letter to the president, he emphasized that a pending proposal to move cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA) is something “you supported in your presidential campaign.” “That process should be allowed to play out. Americans deserve leadership that won’t move the goalposts on them in the middle of the game,” Beshear said, noting that he was among the tens of thousands who submitted public comments in favor of the reform after it was initiated under the Biden administration, “demonstrating broad public interest in rescheduling.” “I joined that effort because this is about helping people. Rescheduling would provide suffering patients the relief they need,” the governor said. “It would ensure communities are safer—because legal medical products reduce the illicit market. It would provide new, meaningful research on health benefits.” Beshear also mentioned a letter to DEA he signed onto last year urging rescheduling, “because the jury is no longer out on marijuana. It has medical benefits.” Back on the state level, the governor recently said he acknowledges that “it’s taken longer than we would have liked” to stand up the industry since he signed medical marijuana legalization into law in 2023. In recognition of that delayed implementation, he recently signed an executive order to waive renewal fees for patients who get their cards this year so that they don’t get charged again before retailers open. And another order he signed providing protections for qualified patients who obtain medical marijuana outside of Kentucky “will stay in place.” Beshear separately announced in May that the state has launched a new online directory that lets people see where medical cannabis dispensaries will be opening near them. He emphasized that the state has been working to deliver access to patients “at the earliest possible date,” and that involved expediting the licensing process. The governor in January also ceremonially awarded the commonwealth’s first medical marijuana cards. *— Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.* *Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. —* Meanwhile, the governor sent a letter to Kentucky’s congressional delegation in January, “urging them to take decisive action to protect the constitutional rights of our law abiding medical cannabis patients” by repealing the federal ban on gun possession by people who use marijuana. That came after bipartisan Kentucky senators filed legislation that similarly called on the state’s federal representatives to take corrective action, which Beshear said he supports but would like to see even more sweeping change on the federal level. The federal Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) warned Kentucky residents late last year that, if they choose to participate in the state’s medical marijuana program, they will be prohibited from buying or possessing firearms under federal law. As far as the implementation of the state’s medical cannabis law goes, Beshear said in his State of the Commonwealth address in January that patients will have access to cannabis sometime “this year.” He also later shared tips for patients to find a doctor and get registered to participate in the cannabis program. Health practitioners have been able to start assessing patients for recommendations since the beginning of December. While there currently aren’t any up-and-running dispensaries available to patients, Beshear has further affirmed that an executive order he signed in 2023 will stay in effect in the interim, protecting patients who possess medical cannabis purchased at out-of-state licensed retailers. During last year’s November election, Kentucky also saw more than 100 cities and counties approve local ordinances to allow medical cannabis businesses in their jurisdictions. The governor said the election results demonstrate that “the jury is no longer out” on the issue that is clearly supported by voters across partisan and geographical lines. *Photo courtesy of California State Fair.* The post Kentucky Cultivator Harvests State’s First Medical Marijuana Crop As Governor Predicts Farmers Will ‘Grow A Whole Lot More’ appeared first on Marijuana Moment. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Advertisements by state-licensed medical marijuana businesses in Mississippi don’t enjoy First Amendment free-speech protections. US Supreme Court rejects challenge to Mississippi’s marijuana advertising ban. < Back US Supreme Court rejects challenge to Mississippi’s marijuana advertising ban May 5, 2025 Chris Roberts MJ Biz Daily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Advertisements by state-licensed medical marijuana businesses in Mississippi don’t enjoy First Amendment free-speech protections. US Supreme Court rejects challenge to Mississippi’s marijuana advertising ban is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Cannabis shoppers in Ohio can now purchase up to 2.5 ounces of cannabis flower. The rule change allows for increased purchasing limits. Dispensaries conducted nearly $400 million in adult-use sales in the first seven months. Lawmakers were accused of withholding tax revenue. Republican lawmakers are pushing to scale back the state’s cannabis legalization law. < Back Ohio Raises Cannabis Purchasing Limit Jun 9, 2025 Graham Abbott Ganjapreneur Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Cannabis shoppers in Ohio can now purchase up to two and a half ounces of cannabis flower from licensed dispensaries under a rule change announced last week by the Division of Cannabis Control (DCC). Previously, cannabis purchases were capped at a single ounce for flower to prevent product shortages during the adult-use industry’s launch last year. “Since non-medical cannabis sales began in August 2024, the market has demonstrated the ability to support both medical marijuana patients and non-medical consumers alike,” the agency wrote in a guidance published last week. The rule change took effect immediately on Wednesday, but while the purchasing limits for cannabis flower products have increased, the regulations on other cannabis products remain unchanged. Outside of cannabis flower, Ohio state law sets a 15,000mb total THC cap on adult-use cannabis purchases — dispensaries are expected to honor the limit by tallying up the total THC content being bought by consumers, including cannabis concentrates, edibles, beverages, and vaporizers. Licensed cannabis dispensaries in Ohio conducted nearly $400 million in adult-use sales during the first seven months of the legal market. In March, lawmakers were accused of withholding more than $10 million in adult-use cannabis tax revenue that was supposed to be earmarked for local governments that had opted to allow cannabis businesses. Meanwhile, Republican lawmakers have more recently been pushing to scale back the state’s voter-approved cannabis legalization law through at least two different proposals: one to cap THC limits in cannabis concentrates and impose other limits that were left out of the voter-approved bill, and one to cut back on the number of home grow plants allowed under state law. < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5

Regulators are examining cannabis packaging companies for making unsubstantiated claims about their products' ability to prevent mold, according to a report from MJBizDaily. < Back Cannabis packaging companies scrutinized over mold claims Nov 12, 2025 Margaret Jackson MJbizDaily Article Link Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Regulators are scrutinizing cannabis packaging businesses, targeting companies that make unverified claims about their products’ ability to prevent mold. Cannabis packaging companies scrutinized over mold claims is a post from: MJBizDaily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs < Previous Next > Recent Reviews Cake Boss - Fluent, Clearwater (Florida Medical) Cake Boss, available at Fluent dispensary in Clearwater, Florida, is a slightly indica-dominant hybrid strain (60% indica, 40% sativa) th... Cherry AK-47 by Grow West - RISE Dispensary (Silver Spring, Maryland) When a strain name includes both "Cherry" and "AK-47," you can expect two things: a blast of fruity goodness and the kind of impact that... Cookies & Alt Sol "Madrina" Strain Review - Takoma Wellness Center Madrina, cultivated by Alt Sol and available at Takoma Wellness Center in Washington, DC, comes with a reputation as bold as its name. In... 1 2 3 4 5